Medicine
from24/7 Wall St.
1 day agoWhy Tempus AI Stock Is Up Today - And What to Watch Before Next Week's Earnings
Tempus launched an AI-driven Pan-Cancer HRD-RNA test identifying homologous recombination deficiency via RNA, boosting stock momentum ahead of its Q4 2025 earnings report.